Cooley Receives Multiple Life Sciences Awards

New York – September 5, 2025 – Two Cooley life sciences attorneys received awards from LMG Life Sciences in its 13th annual Americas Awards program.

The firm’s Washington, DC-based Eric Greig was named Regulatory Attorney of the Year for Pricing and Reimbursement. Greig recently joined the firm as a partner advising clients on healthcare regulatory, market access and reimbursement strategies across the pharmaceutical, medical device, digital health, biotechnology and healthcare services sectors.

Additionally, Palo Alto-based Josh Seidenfeld was named Venture Capital Attorney of the Year. Seidenfeld serves as global chair of Cooley’s digital health group.

The firm was also honored in an Impact Deal of the Year for its representation of Arsenal Biosciences in its $325 million Series C financing round – a deal co-led by Seidenfeld and partner Sara Semnani. Cooley previously advised the company on its $220 million Series B financing and its collaboration with Bristol Myers Squibb in 2021.

This marks the fifth consecutive year in which Cooley received at least one major award granted by LMG Life Sciences.

Life sciences breakthroughs happen with Cooley. The firm’s collaborative approach draws upon unparalleled life sciences sector experience to drive strategic solutions and resolve challenges.

The firm’s practitioners are versed in all aspects of life sciences technologies, delivering an unmatched combination of innovative legal guidance, deep industry knowledge and practical understanding of clients’ needs. Many of our lawyers worked as pharmaceutical marketing professionals, business consultants, financial leaders, biotech researchers and in-house counsel at life sciences companies before joining the Cooley team. The firm serves as trusted counsel to 2,500+ public and private life sciences company clients worldwide, including nearly 50% of the Nasdaq Biotechnology Index. Clients include innovative biotech and specialty pharmaceutical companies at the forefront of new technologies, including cell and gene therapies, artificial intelligence-led drug discovery and new vaccine technologies.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.